Trial Profile
A Randomized, Double-blind, Multicenter Phase III Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Jun 2022
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Catequentinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 25 Jun 2020 New trial record